Longeveron
Miami
About Longeveron
Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Longeveron's primary investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of healthy adult donors. Lomecel-B™ exhibits various potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects. These properties make it applicable across a range of diseases. Longeveron is currently conducting clinical trials for Lomecel-B™ in three areas: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $69.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:LGVN
- Website: longeveron.com
- Phone: 305.909.0840
Industries & Categories
Biotechnology, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/longeveron-16784 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.